Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M L Salgaller

Showing results (11-20 of 37) with videos related to

Pageof 4
Sort By:
Journal of Surgical Oncology|June 12, 1998
Use of cellular and cytokine adjuvants in the immunotherapy of cancerM L Salgaller, P A Lodge
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 1, 1997
Expression of MAGE genes in ocular melanoma cell linesP W Chen, T G Murray, M L Salgaller, et al.
Cancer Research|May 1, 1993
Baculovirus recombinants expressing the human carcinoembryonic antigen geneM L Salgaller, R Bei, J Schlom, et al.
International Journal of Cancer|October 21, 1996
MAGE-1 and MAGE-3 or -6 expression in neuroblastoma-related pediatric solid tumorsH Ishida, T Matsumura, M L Salgaller, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1996
Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cellsF M Marincola, L Rivoltini, M L Salgaller, et al.
Cancer Research|October 15, 1996
Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptidesM L Salgaller, F M Marincola, J N Cormier, et al.
CA: a Cancer Journal for Clinicians|February 24, 2001
Dendritic cell-based immunotherapy for prostate cancerB A Tjoa, P A Lodge, M L Salgaller, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1993
Evaluation of human carcinoembryonic-antigen (CEA)-transduced and non-transduced murine tumors as potential targets for anti-CEA therapiesP H Hand, P F Robbins, M L Salgaller, et al.
Cancer Immunology, Immunotherapy : CII|August 1, 1994
Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptideM L Salgaller, J S Weber, S Koenig, et al.
Cancer Research|November 1, 1995
Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptidesM L Salgaller, A Afshar, F M Marincola, et al.
Pageof 4

Showing results (11-20 of 37) with videos related to

Sort By:
Pageof 4
Journal of Surgical Oncology|June 12, 1998
Use of cellular and cytokine adjuvants in the immunotherapy of cancerM L Salgaller, P A Lodge
Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 1, 1997
Expression of MAGE genes in ocular melanoma cell linesP W Chen, T G Murray, M L Salgaller, et al.
Cancer Research|May 1, 1993
Baculovirus recombinants expressing the human carcinoembryonic antigen geneM L Salgaller, R Bei, J Schlom, et al.
International Journal of Cancer|October 21, 1996
MAGE-1 and MAGE-3 or -6 expression in neuroblastoma-related pediatric solid tumorsH Ishida, T Matsumura, M L Salgaller, et al.
Journal of Immunotherapy with Emphasis on Tumor Immunology : Official Journal of the Society for Biological Therapy|July 1, 1996
Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cellsF M Marincola, L Rivoltini, M L Salgaller, et al.
Cancer Research|October 15, 1996
Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptidesM L Salgaller, F M Marincola, J N Cormier, et al.
CA: a Cancer Journal for Clinicians|February 24, 2001
Dendritic cell-based immunotherapy for prostate cancerB A Tjoa, P A Lodge, M L Salgaller, et al.
Cancer Immunology, Immunotherapy : CII|January 1, 1993
Evaluation of human carcinoembryonic-antigen (CEA)-transduced and non-transduced murine tumors as potential targets for anti-CEA therapiesP H Hand, P F Robbins, M L Salgaller, et al.
Cancer Immunology, Immunotherapy : CII|August 1, 1994
Generation of specific anti-melanoma reactivity by stimulation of human tumor-infiltrating lymphocytes with MAGE-1 synthetic peptideM L Salgaller, J S Weber, S Koenig, et al.
Cancer Research|November 1, 1995
Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptidesM L Salgaller, A Afshar, F M Marincola, et al.
Pageof 4